STRIKE: Silicosis Treatment with Infliximab – A Key Evaluation (ACTRN12625000499482)

The STRIKE clinical trial at the Alfred Hospital tests whether the medication infliximab can reduce lung inflammation in people with advanced silicosis from artificial stone exposure. This study offers hope for a potential treatment for silicosis, a progressive lung disease that currently has no approved therapy.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Ryan Hoy

Key inclusion data

Key Inclusion Criteria: Silicosis with progressive massive fibrosis from artificial stone exposure who have significant lung function decline. Exclusion Criteria include: Ongoing occupational silica exposure; Recent or chronic serious infections; Use of immunosuppressants in the past 4 weeks; History of cancer in the last 5 years.